Screening for prostate cancer--the controversy that refuses to die.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

130 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Interventions to improve decision making and reduce racial and ethnic disparities in the management of prostate cancer: a systematic review.Journal of general internal medicine · 2012
   Pooled it
2. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2010
   Pooled it
3. Systematic Review of Commercially Available Mobile Phone Applications for Prostate Cancer Education.American journal of men's health
   Pooled it
4. The Impact of 4 Risk Communication Interventions on Cancer Screening Preferences and Knowledge.Medical decision making : an international journal of the Society for Medical Decision Making · 2022
   Trial
5. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?European urology · 2019
   Trial
6. Historical prostate cancer screening and treatment outcomes from a single institution.Clinical medicine & research · 2012
   Trial
7. CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
   Review
8. Integrated Urinary and Tissue Proteomic Signatures Reveal Core and Progression Biomarkers in MRI-Visible and MRI-Non-Visible Prostate Cancer.Life (Basel, Switzerland) · 2026
   Article
9. Therapeutic Potential of Plant- and Marine-Derived Bioactive Compounds in Prostate Cancer: Mechanistic Insights and Translational Applications.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
10. Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey.Journal of personalized medicine · 2024
    Article
11. Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.BJU international · 2024
    Article
12. Spatio-temporal variation in prostate cancer testing in Stockholm: A population-based study.PloS one · 2024
    Article
13. Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings.Cancers · 2023
    Article
14. Evaluation of Matrix Metalloproteases by Artificial Intelligence Techniques in Negative Biopsies as New Diagnostic Strategy in Prostate Cancer.International journal of molecular sciences · 2023
    Article
15. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.Communications biology · 2022
    Article
16. Multicancer Early Detection: Learning From the Past to Meet the Future.Journal of the National Cancer Institute · 2022
    Article
17. Construction of a Comprehensive Diagnostic Scoring Model for Prostate Cancer Based on a Novel Six-Gene Panel.Frontiers in genetics · 2022
    Article
18. Emerging strategies for treating metastasis.Nature cancer · 2021
    Article
19. The "sugar-coated bullets" of cancer: Tumor-derived exosome surface glycosylation from basic knowledge to applications.Clinical and translational medicine · 2020
    Review
20. Prostate cancer screening research can benefit from network medicine: an emerging awareness.NPJ systems biology and applications · 2020
    Review

70 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  Mortality results from a randomized prostate-cancer screening trial.2009
• Comment on
  Screening and prostate-cancer mortality in a randomized European study.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as